Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway ; volume:11 ; number:1 ; day:27 ; month:3 ; year:2018 ; pages:1-16 ; date:12.2018
Journal of hematology & oncology ; 11, Heft 1 (27.3.2018), 1-16, 12.2018
- Urheber
-
Tremblay-LeMay, Rosemarie
- Beteiligte Personen und Organisationen
-
Rastgoo, Nasrin
Chang, Hong
SpringerLink (Online service)
- DOI
-
10.1186/s13045-018-0589-1
- URN
-
urn:nbn:de:101:1-2018053020123845463796
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:28 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tremblay-LeMay, Rosemarie
- Rastgoo, Nasrin
- Chang, Hong
- SpringerLink (Online service)
Ähnliche Objekte (12)
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Factors correlating the expression of PD-L1
Optimized PD-L1 scoring of gastric cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Factors correlating the expression of PD-L1
Optimized PD-L1 scoring of gastric cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Factors correlating the expression of PD-L1